tiprankstipranks
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
US Market

TransCode Therapeutics (RNAZ) Income Statement

Compare
301 Followers

TransCode Therapeutics Income Statement

Last quarter (Q3 2024), TransCode Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, TransCode Therapeutics's net income was $-2.32M. See TransCode Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ -516.75K$ -98.61K$ -42.47K$ 0.00$ 0.00
Operating Expenses
$ 19.42M$ 17.59M$ 5.87M$ 726.60K$ 456.87K
Depreciation and Amortization
$ 516.75K$ 98.61K$ 42.47K$ 726.60K$ 456.87K
EBITDA
$ -17.97M$ -17.47M$ -6.11M$ 0.00$ 0.00
Operating Income
$ -19.42M$ -18.67M$ -6.15M$ -726.60K$ -456.87K
Other Income/Expenses
$ 872.42K$ 1.10M$ -692.26K$ -1.62M$ -150.35K
Pretax Income
$ -18.55M$ -17.56M$ -6.84M$ -2.34M$ -607.21K
Net Income
$ -18.55M$ -35.13M$ -6.94M$ -2.74M$ -764.14K
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -103.61$ -2.20K$ -658.80$ -343.19$ -119.27
Diluted EPS
$ -103.61$ -2.17K$ -658.80$ -343.19$ -119.27
Weighted Average Shares Outstanding
179.00K 16.00K 10.53K 7.98K 6.41K
Weighted Average Shares Outstanding (Diluted)
179.01K 16.22K 10.53K 7.98K 6.41K
Currency in USD

TransCode Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis